Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 12/20 | 0.60 |
| ▸ | HTR1B | P28222 | 12/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | THPO | P40225 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HTR1F | P30939 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 3/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9875206 | 0.85 | HTR1D (0.60) | HTR1DHTR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4540063 | 0.81 | HTR1D (0.60) | HTR1DHTR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8915192 | 0.81 | CYP1A2 (0.68) | HTR1DHTR1BCYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL9764720 | 0.81 | HTR1D (0.66) | HTR1DHTR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL252678 | 0.81 | HTR1D (0.62) | HTR1DHTR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3222849 | 0.80 | HTR1D (0.77) | HTR1DHTR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4541547 | 0.80 | HTR1D (0.77) | HTR1DHTR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8416068 | 0.80 | HTR1D (0.62) | HTR1DHTR1BCYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL9764506 | 0.79 | HTR1D (0.65) | HTR1DHTR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9874164 | 0.76 | HTR1D (0.68) | HTR1DHTR1BCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2400986-B1 | ENHANCED MIGRAINE TREATMENTS BASED ON GHRELIN MIMETICS | HELSINN HEALTHCARE SA (CH) | 2015-10-14 | — | — | EP | disclosed |
| EP-2838517-A1 | ORALLY AVAILABLE PHARMACEUTICAL FORMULATION SUITABLE FOR IMPROVED MANAGEMENT OF MOVEMENT DISORDERS | Contera Pharma APS (DK) | 2015-02-25 | — | — | EP | disclosed |
| US-8673947-B2 | Enhanced migraine treatments based on ghrelin mimetics | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130289068-A1 | ENHANCED MIGRAINE TREATMENTS BASED ON GHRELIN MIMETICS | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2013156035-A1 | ORALLY AVAILABLE PHARMACEUTICAL FORMULATION SUITABLE FOR IMPROVED MANAGEMENT OF MOVEMENT DISORDERS | CONCIT PHARMA APS (DK) | 2013-10-24 | — | — | WO | disclosed |
| US-8486976-B2 | Enhanced migraine treatments based on ghrelin mimetics | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2400986-A1 | ENHANCED MIGRAINE TREATMENTS BASED ON GHRELIN MIMETICS | Helsinn Therapeutics (U.S.), Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20100222388-A1 | Enhanced Migraine Treatments Based on Ghrelin Mimetics | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2010-09-02 | — | — | US | disclosed |
| WO-2010099522-A1 | ENHANCED MIGRAINE TREATMENTS BASED ON GHRELIN MIMETICS | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289068-A1 | ENHANCED MIGRAINE TREATMENTS BASED ON GHRELIN MIMETICS | HTR1E, HTR1B, HTR3B | HTR1D 6/4885HTR1B 2/4885CYP1A2 1966/4885 |
| US-20100222388-A1 | Enhanced Migraine Treatments Based on Ghrelin Mimetics | HTR1E, HTR1B, HTR3B | HTR1D 6/4885HTR1B 2/4885CYP1A2 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.